Science AI Journal
Medicine · Research topic

Open research questions in Pulmonary Hypertension Research and Treatments

124 unresolved questions extracted from the limitations and future-work sections of 369 Pulmonary Hypertension Research and Treatments papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The study only investigated the effects of ERα on RVECs. The study did not investigate the effects of ERα on other cell types in the RV. The study used a limited number of experimental conditions.

    Sexually Dimorphic Role of Estrogen Receptor α in Preserving Right Ventricular Endothelial Integrity · 2026 · DOI

  • Investigate the effects of ERα on other cell types in the RV. Examine the role of ERα in human RV disease. Explore the therapeutic potential of targeting ERα in RV disease.

    Sexually Dimorphic Role of Estrogen Receptor α in Preserving Right Ventricular Endothelial Integrity · 2026 · DOI

  • no curative treatment currently exists for PH, - the study is based on experimental rat models, - the analysis is limited to three publicly available transcriptomic datasets

    Integrated Analysis of Rat Pulmonary Hypertension Datasets Identifies Candidate circRNA Networks in Hypoxia-Exposed Pulmonary Artery Tissue · 2026 · DOI

  • further research into the molecular mechanisms underlying PH, - identification of potential therapeutic targets, - investigation of circRNA expression in renal disease and hypertension

    Integrated Analysis of Rat Pulmonary Hypertension Datasets Identifies Candidate circRNA Networks in Hypoxia-Exposed Pulmonary Artery Tissue · 2026 · DOI

  • investigate the long-term effects of imatinib mesylate and sirolimus, - study the effects of imatinib mesylate and sirolimus on a larger population, - explore the underlying mechanisms of imatinib mesylate and sirolimus in inhibiting fibroproliferation and EndMT

    Imatinib Mesylate and Sirolimus Inhibit Vascular Fibroproliferative Remodeling in Pulmonary Vein Stenosis · 2026 · DOI

  • The underlying cellular mechanisms of PVS development and progression are not well understood. Current therapies are often insufficient to control disease progression and recurrence.

    Imatinib Mesylate and Sirolimus Inhibit Vascular Fibroproliferative Remodeling in Pulmonary Vein Stenosis · 2026 · DOI

  • exploring the therapeutic implications of estrogen inhibitors - targeting protein methyltransferases or demethylases - understanding the epigenetic mechanisms of the development of PAH

    Exploring the pathogenesis of pulmonary vascular disease · 2024 · DOI

  • Published evidence specifically addressing pregnancy with uncorrected DORV and Eisenmenger physiology remains sparse.

    Favorable maternal and neonatal outcomes in probable Eisenmenger physiology with suspected DORV: a case report and literature review · 2026 · DOI

  • PANoptosis, an inflammatory form of programmed cell death, remains understudied in the context of PAH.

    Identification of a PANoptosis-related gene signature reveals therapeutic potential of SFRP2 in pulmonary arterial hypertension · 2025 · DOI

  • Nevertheless, clinical translatability remains uncertain, as no studies have yet conclusively validated HNRNPA2B1 as a druggable target in human PAH.

    HNRNPA2B1: a novel target in pulmonary arterial hypertension · 2025 · DOI

  • While small noncoding microRNAs (miRNAs) are crucial regulators of RV remodeling, the biomarker potential of serum miRNAs in this process is little known.

    Circulating miRNA-486 as a novel diagnostic biomarker for right ventricular remodeling · 2025 · DOI

  • The insulin receptor substrate-1 (IRS-1) plays a crucial role in the insulin signaling pathway; however, its function in PAH is still not fully understood.

    Role of insulin signaling dysregulation in pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension · 2025 · DOI

  • Background: ICU), representing a challenging condition that has not been extensively studied.

    Global, regional and national trends in the burden of persistent pulmonary hypertension of the newborn and essentials of its management from 1993 to 2023: a scoping review · 2025 · DOI

  • BACKGROUND: Abnormal glycolytic metabolism plays a significant role in pulmonary vascular remodeling in idiopathic pulmonary arterial hypertension (IPAH), yet the specific mechanisms remain unclear.

    Combined analysis of single-cell and bulk transcriptome sequencing data identifies critical glycolysis genes in idiopathic pulmonary arterial hypertension · 2025 · DOI

  • Although accumulating evidence shows the importance of interleukin (IL)-6 in the pathogenesis of PAH, the target cells of IL-6 are poorly understood.

    IL-6/gp130 signaling in CD4 + T cells drives the pathogenesis of pulmonary hypertension · 2024 · DOI

  • This review will elucidate what kind of clinical and biological barriers and gaps in knowledge need to be solved and how this has impacted in the development of clinical trials.

    Inhaled NO at a crossroads in cardiac surgery: current need to improve mechanistic understanding, clinical trial design and scientific evidence · 2024 · DOI

  • Background Right ventricular systolic dysfunction (RVSD) in patients with sepsis is an area of growing interest, but its prognostic significance remains unclear and additional tools are needed to improve our understanding.

    Prognostic value of right ventricular free wall strain in patients with sepsis · 2024 · DOI

  • Its role in pulmonary hypertension (PH) associated with secundum atrial septal defect (ASD), which is the most common adult congenital heart disease (CHD), remains poorly understood.

    Right ventricular fibrosis in adults with uncorrected secundum atrial septal defect and pulmonary hypertension: a cardiovascular magnetic resonance study with late gadolinium enhancement, native T1 and extracellular volume · 2024 · DOI

  • The molecular mechanisms driving the comorbidity of PAH and CMP are not well understood. There is a need for therapeutic agents that target the underlying mechanisms of PAH-CMP comorbidity.

    HYAL3 as a therapeutic target for pulmonary arterial Hypertension–Cardiomyopathy comorbidity: an integrative analysis combined with machine learning and SHAP value interpretation · 2026 · DOI

  • The importance of recognizing right ventricular myocardial strain in cases of malignancy-associated pulmonary hypertension. The potential for 18F-FDG PET/CT to detect right ventricular myocardial strain.

    Right Ventricular Strain Secondary to Tumor-Induced Pulmonary Artery Obstruction: An Incidental 18 F-FDG PET/CT Finding in Small Cell Pancoast Tumor · 2026 · DOI

  • PAH is a complex and multifactorial disease. The development of novel therapeutic agents for PAH is challenging due to the limited understanding of the disease's underlying mechanisms. The use of traditional Chinese medicine as a source of novel therapeutics poses regulatory and standardization challenges.

    Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial · 2026 · DOI

  • Further studies are needed to evaluate the long-term efficacy and safety of TPN171H in patients with PAH. The development of future therapies targeting the PDE5 pathway may be informed by the study's findings. Traditional Chinese medicine may be a valuable source of novel therapeutics for various diseases.

    Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial · 2026 · DOI

  • The clinical evaluation of PH is inherently multimodal. Computed tomography has limitations in terms of quantitative vascular information. There is a need for personalized medicine approaches to PH diagnosis and treatment.

    Anthropometry, sex, and age at diagnosis affect pulmonary blood volume quantification from computed tomography pulmonary angiography in pulmonary hypertension assessment · 2026 · DOI

  • The influence of anthropometrics, sex, and age at diagnosis on AI-derived pulmonary blood volumes is poorly characterized. There is a need for a comprehensive evaluation of how these factors affect PBV quantification.

    Anthropometry, sex, and age at diagnosis affect pulmonary blood volume quantification from computed tomography pulmonary angiography in pulmonary hypertension assessment · 2026 · DOI

  • Prostacyclin—Inhaled PERFECT Phase 3 RCT, PH-COPD confirmed 12 weeks ↑ Adverse events, ↓ Early termination, small treprostinil (2024) cross-over study (terminated 6MWD N, heterogeneous early) population PERFECT— Subgroup, crosssPAP >40 mmHg, 12 weeks Suggestion of benefit Exploratory, nonpost hoc over study FEV1 > 40% (terminated early) planned Bajwa et al.

    Prevalence, pathogenesis, and clinical impact of pulmonary hypertension associated with chronic obstructive pulmonary disease · 2026 · DOI

Most-cited papers in Pulmonary Hypertension Research and Treatments

Most recent work

Find a gap in your own Pulmonary Hypertension Research and Treatments sub-topic

This page shows what the Pulmonary Hypertension Research and Treatments literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
124 open questions have been extracted from the limitations and future-work passages of 369 Pulmonary Hypertension Research and Treatments papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.